The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.
Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews
Abstract
PURPOSE OF REVIEW: Irritable bowel syndrome (IBS) is a common disorder of the gastrointestinal tract, about which there has been considerable recent research. The aim of this article is to briefly review the aspects of IBS pathogenesis that involve the gastrointestinal microbiota, and then to critically appraise the recent and emerging evidence for the use of probiotics and prebiotics in its management. RECENT FINDINGS: The increased risk of developing IBS following gastroenteritis and the co-existence of dysbiosis, elevated luminal gas production and immune activation, indicate that the gastrointestinal microbiota may be a therapeutic target in IBS. Most systematic reviews indicate that probiotics have a beneficial impact on global IBS symptoms, abdominal pain and flatulence. However, recent trials indicate that different probiotics can improve, have no effect, or even worsen symptoms, confirming that benefits are likely to be strain and symptom-specific. There are no recent clinical trials of prebiotics in IBS, although previous studies indicate potential benefit at lower doses. SUMMARY: Clearly, some probiotics have considerable potential in the management of IBS; however, the benefits are likely to be strain-specific. Preliminary studies suggest low doses of prebiotics may improve symptoms of IBS, although further robust clinical trials are required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effectiveness of probiotics in improving IBS symptoms has been tentatively recognized, and several probiotic strains have been demonstrated to benefit patients with IBS [25,26,27].”
In the citing paper
“Given that changes in the gut microbiota have been implicated in the pathogenesis of GI disorders [such as irritable bowel syndrome (IBS)],5–8 there is growing interest in therapies that might influence these changes, such as probiotics.”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [8]
In the citing paper
“An overview of meta-analyses in IBS showed a similar trend, with more supportive evidence available for overall symptom burden and abdominal pain than for flatus.8”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [8]
In the citing paper
“The Consensus Group concluded, with a high level of evidence, that specific probiotics help reduce overall symptom burden and abdominal pain in IBS (Statements 1 and 4: 100% agreement among voters), consistent with previous meta-analyses and reviews.2,8”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [8]
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Prebiotic effects: metabolic and health benefits
Roberfroid, M., Gibson, G. R., Hoyles, L., McCartney, A. L., Rastall, R., Rowland, I., Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., et al. (2010) · British Journal of Nutrition · doi:10.1017/s0007114510003363 · Cited by 2,085
Self-citationSonnenburg, E. D., Zheng, H., Joglekar, P., Higginbottom, S. K., Firbank, S. J., Bolam, D. N., & Sonnenburg, J. L. (2010) · Cell · doi:10.1016/j.cell.2010.05.005 · Cited by 748
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728
Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions
Öhman, L., & Simrén, M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.4 · Cited by 617
Ong, D. K., Mitchell, S. B., Barrett, J. S., Shepherd, S. J., Irving, P. M., Biesiekierski, J. R., Smith, S., Gibson, P. R., & Muir, J. G. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06370.x · Cited by 583
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Staudacher, H. M., Whelan, K., Irving, P. M., & Lomer, M. C. E. (2011) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2011.01162.x · Cited by 436
Self-citationMarshall, J. K., Thabane, M., Garg, A. X., Clark, W. F., Salvadori, M., & Collins, S. M. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.053 · Cited by 375
Research works printed but not linked: 3
- Spiller, 2010, epatol, 8, 125
- Pimentel, 364, N Engl J Med, 22-, 32
- Huertas-Ceballos, 2009, Cochrane Database Syst Rev, 1, CD003019
Cited by
Intestinal permeability – a new target for disease prevention and therapy
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., Tilg, H., Watson, A., & Wells, J. M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0189-7 · Cited by 1,755
“Possibly, the loss of particular TJ proteins such as occludin is a result of increased proteasome-mediated degradation observed in IBS triggered by low-grade inflammation and resulting in increased intestinal permeability [196].”
ResultInfluentialStaudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.159285 · Cited by 590
Self-citationKonturek, P. C., Brzozowski, T., & Konturek, S. J. (2011) · PubMed · Cited by 818
Can probiotics modulate human disease by impacting intestinal barrier function?
Bron, P. A., Kleerebezem, M., Brummer, R.-J., Cani, P. D., Mercenier, A., MacDonald, T. T., Garcia-Ródenas, C. L., & Wells, J. M. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114516004037 · Cited by 499
Brain gut microbiome interactions and functional bowel disorders
Mayer, E. A., Savidge, T., & Shulman, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.037 · Cited by 496
Metadata
- Authors
- Whelan, K.
- Affiliations
- King's College London (GB)
- Corresponding author
- Whelan, Kevin
- ORCID
- Whelan, Kevin
- Venue
- Current Opinion in Clinical Nutrition and Metabolic Care
- Published
- 2011-11
- Volume
- 14
- Issue
- 6
- Pages
- 581-587
- ISSN
- 1363-1950 (ISSN-L)
- OpenAlex
- W2001298761
- Cited by
- 120
- References
- 28
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 8 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 12 · 2015: 14 · 2014: 21 · 2013: 20 · 2012: 11
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Clinical Nutrition & Metabolic Care (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, probiotics, prebiotics, gut microbiota, dysbiosis, IBS pathogenesis, strain-specific effects, abdominal pain, flatulence, gastroenteritis, immune activation
- MeSH terms
- Systematic Reviews as Topic, Dose-Response Relationship, Drug, Flatulence, Humans, Meta-Analysis as Topic, Abdominal Pain, Randomized Controlled Trials as Topic, Probiotics, Gastrointestinal Tract, Irritable Bowel Syndrome, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. https://app.cochat.ai/papers/10.1097/mco.0b013e32834b8082
- The paper
- Whelan, K. (2011). Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Current Opinion in Clinical Nutrition and Metabolic Care. https://doi.org/10.1097/mco.0b013e32834b8082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.